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2-Oxoglutarate regulates binding of hydroxylated
hypoxia-inducible factor to prolyl hydroxylase
domain 2†
Martine I. Abboud, a Tom E. McAllister, a Ivanhoe K. H. Leung, ab
Rasheduzzaman Chowdhury, a Christian Jorgensen, c Carmen Domene,ad
Jasmin Mecinovic´, ae Kerstin Lippl,a Rebecca L. Hancock,a Richard J. Hopkinson, af
Akane Kawamura, a Timothy D. W. Claridge *a and Christopher J. Schofield *a
Prolyl hydroxylation of hypoxia inducible factor (HIF)-a, as catalysed
by the Fe(II)/2-oxoglutarate (2OG)-dependent prolyl hydroxylase
domain (PHD) enzymes, has a hypoxia sensing role in animals.
We report that binding of prolyl-hydroxylated HIF-a to PHD2 is
B50 fold hindered by prior 2OG binding; thus, when 2OG is limiting,
HIF-a degradation might be inhibited by PHD binding.
The chronic response to limitingO2 in animals involves upregulation
of multiple genes as enabled by the a,b-heterodimeric hypoxia
inducible factors (HIFs). Under normoxia, HIF-a subunits are
eﬃciently degraded by proteasomes; in hypoxia, HIF-a subunits
accumulate, so enabling the a,b-HIF complex to promote expression
of HIF target genes, including genes for biomedicinally important
proteins, such as the vascular endothelial growth factor and
erythropoietin.1 There is thus a considerable interest in the
therapeutic manipulation of the HIF system (Fig. S1, ESI†).2,3
trans-4-Prolyl hydroxylation of HIF-a substantially (B103 fold)
increases the strength of its binding to the von Hippel–Lindau
protein (pVHL), the targeting component of a ubiquitin E3 ligase.4–7
HIF-a prolyl hydroxylation occurs at P402 and P564 (HIF-1a) in
the N- and C-terminal oxygen dependent degradation domains
(NODD/CODD, respectively), and is catalysed by human Fe(II)- and
2-oxoglutarate (2OG)-dependent oxygenases (PHD1-3),8,9 the most
important of which is likely PHD2 (Fig. S2, ESI†).10 Evidence from
studies with proteins, cells, and animals supports the proposal
that PHD activity is limited by O2 availability. PHD catalysis
involves binding of 2OG, HIF-a, then O2, to the active site, with
CO2 and succinate being produced as coproducts (Fig. S3,
ESI†).11–13 Evidence has been presented that the PHDs act as
hypoxia sensors, including by the manifestation of an unusually
slow reaction with O2.
11,12 PHD catalysis has the potential to be
regulated by Fe(II) and 2OG availability, as well as by succinate
and other TCA cycle intermediates.14,15 C4 trans prolyl hydroxylation
increases the fraction of the C4-exo prolyl conformation, as observed
when HIF-a is complexed with pVHL,4–7,16 likely in part due to the
‘gauche’ stereoelectronic effect.17 The interactions of HIF-a with
pVHL and the PHDs are of interest from a chemical perspective
because of the profound effect of hydroxylation on biological
function. Here, we report evidence that the presence of the 2OG
cosubstrate at the PHD2 active site can regulate binding of
unhydroxylated versus prolyl hydroxylated HIF-a (Fig. 1).
We initially investigated the binding of 19-mer HIF-1a CODD
and hydroxylated CODD (hyCODD) peptides to recombinantly
expressed PHD2181–426 (tPHD2) using non-denaturing mass spectro-
metry (ESI-MS).18,19 The results indicated that CODD binds strongly
not only to tPHD2Fe, but also to apo-tPHD2 (Fig. 2). Addition of
2OG to a 1 : 1 mixture of apo-tPHD2CODD did not lead to
Fig. 1 Outline role of PHD-catalysed HIF-a hydroxylation.
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observation of an apo-tPHD22OG complex, consistent with 2OG
binding to the Fe(II) in catalysis.20 Analysis of an equimolar
mixture of apo-tPHD2, Fe(II), 2OG, and CODD manifested
masses corresponding to complexes of tPHD2FeCODD-OH
and tPHD2FeCODD-OHsuccinate, but not any observable
quaternary complex with 2OG (Fig. 2). These results indicate
that CODD and hyCODD bind to apo-tPHD2/tPHD2Fe (Fig. 2).
Having shown that the interaction between tPHD2 and CODD
is preserved in the gas phase, we then carried out solution
studies. NMR studies21,22 using 15N-labelled PHD2181–402 showed
that CODD and hyCODD bind with approximately equal affinity
to apo-PHD2181–402 and PHD2181–402Zn (i.e. both saturated apo-
PHD2181–402 and PHD2181–402Zn at 2.7-fold excess) (Fig. 3A and B).
The spectrum of the PHD2181–402Zn2OGCODD complex was
observed as reported.22 By contrast, hyCODD only showed weak
binding to PHD2181–402Zn2OG (Fig. 3C). The 1H–15N HSQC spectra
of apo-PHD2181–402hyCODD and apo-PHD2181–4022OGhyCODD are
similar in the presence of excess hyCODD (Fig. 3D). The overall
results imply hyCODD binding is blocked by the presence of 2OG;
as anticipated, binding of CODD to PHD2Zn is not hindered by
2OG.22,23
To investigate the relative aﬃnities of hyCODD and CODD
to tPHD2, a fluorescence polarisation assay with N-terminal
fluorescein-tagged CODD (CODD*) was developed (Fig. S4,
ESI†). Consistent with the NMR and MS data, CODD and
hyCODD bind to apo- and metallated-tPHD2 equally strongly
(within a 2-fold diﬀerence). With tPHD2Zn2OG, hyCODD was
observed to bind B50-fold less strongly than CODD (Fig. S5,
ESI†). Isothermal calorimetry results showed that both CODD
and hyCODD bind with similar aﬃnity to apo-tPHD2 (9.4  4.5
and 4.6  1.4 mM, respectively); by contrast, CODD, but not
hyCODD, was observed to bind to tPHD2Zn2OG (KD = 1.8 
0.4 mM) (Fig. S6, ESI†). Addition of hyCODD displaced 2OG
from tPHD2Zn2OG as observed by NMR, implying hyCODD
and 2OG compete for binding to the metal complexed tPHD2
(Fig. S7, ESI†). CODD does not displace 2OG, consistent with
the FP observations (Fig. S5, ESI†) and the binding require-
ments of the catalytic cycle (Fig S2, ESI†).
Mutation of genes encoding for TCA cycle enzymes are
observed in tumours with consequent eﬀects on metabolite
levels, resulting in proposed inhibition of human 2OG oxygenases,
including the PHDs, so promoting tumorigenesis.14,15 The eﬀects
of TCA cycle intermediates (Fig. S8, ESI†) on CODD/hyCODD
binding to tPHD2Zn were investigated by NMR; of the tested
compounds, only fumarate and succinate were observed to bind to
tPHD2Zn, consistent with previous reports.15 By contrast with
2OG, the binding of fumarate or succinate was only weakly
disrupted by hyCODD (Fig. S9, ESI†), implying the ‘additional’
carbonyl of 2OG has a role in hindering hyCODD, but not CODD,
binding to the tPHD2metal complex. The observation of simulta-
neous binding of succinate and hyCODD to tPHD2 is consistent
with the MS results (Fig. 2d).
Analysis of crystallographic data of tPHD2HIF-a complexes
indicates the metal chelated 2OG C1 carboxylate may hinder
hyCODD, but not CODD, binding (Fig. 4). By contrast, modelling
of succinate binding (using tPHD2 structures and those of succinate
complexed with other 2OG oxygenases)15,22 indicates that it will
not manifest a steric clash with hyCODD (Fig. S10, ESI†).
Crystallographic analysis implies that in the tPHD2Mn2OGODD
Fig. 2 Deconvoluted non-denaturing ESI-MS spectra showing CODD
substrate, Fe(II) cofactor, and 2OG cosubstrate binding to tPHD2. (a) Black
trace: 1 : 1, tPHD2 :CODD; (b) purple trace: 1 : 1 : 1, tPHD2 : Fe : CODD;
(c) green trace: 1 : 1 : 1, tPHD2 : 2OG :CODD; (d) red trace: 1 : 1 : 1 : 1,
tPHD2 : Fe : 2OG :CODD. For assay conditions, see Materials and methods.
Fig. 3 1H–15N HSQC binding studies reveals 2OG hinders binding of
hyCODD, but not CODD, to PHD2Zn(II). (A) Overlays of 1H–15N HSQC
spectra for apo-15N-PHD2181–402CODD (blue) and apo-15N-PHD2181–402
hyCODD (red); mixture: 150 mM apo-15N-PHD2181–402, 700 mM CODD or
550 mM hyCODD. (B) Overlays of 1H–15N HSQC spectra for 15N-PHD2181–402
ZnCODD (blue) and 15N-PHD2181–402ZnhyCODD (red); mixture: 150 mM
apo-15N-PHD2181–402, 300 mM Zn(II), 400 mMCODD/hyCODD. (C) Overlays of
a region of the 1H–15N HSQC spectra for 15N-PHD2181–402Zn2OG with 0 mM
hyCODD (blue), 75 mM hyCODD (red), 112.5 mM hyCODD (green), 150 mM
hyCODD (purple) and 300 mM hyCODD (orange). Mixture: 50 mM apo-15N-
PHD2181–402, 100 mM Zn(II), 50 mM 2OG. (D) Overlays of the
1H–15N HSQC
spectra for a mixture of 150 mM apo-15N-PHD2181–402 and 400 mM hyCODD
(blue) and a mixture of 50 mM apo-15N-PHD2181–402, 300 mM 2OG, 400 mM
hyCODD (red). Buffering was with 50 mM Tris-D11, pH 6.6, in 95% H2O,
5% D2O.
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complexes, the substrate prolyl ring adopts the C4-endo con-
formation which changes to the C4-exo on hydroxylation.4,5,17
This proposal is supported by the reported observation that cis,
but not trans, 4-fluoro prolyl CODD is a tPHD2 substrate17 and
by the 19F NMR studies which show a lack of eﬃcient binding
of trans-4-fluoro prolyl CODD to tPHD2Fe2OG (Fig. S11, ESI†).
Modelling studies imply the C4-exo, rather than the C4-endo,
conformation of trans-4-prolyl hydroxylated CODD will lead to a
clash between the hyCODD alcohol and the 2OG C1 carboxylate
(Fig. S12–S18, ESI†).
Whether hyCODD competes with 2OG and/or NODD was
investigated using 1D CLIP HSQC (with selective 13C-inversion)
NMR using 13C-2OG and 13C-NODD.24,25 The addition of unlabelled
CODD to tPHD2Zn2OGNODD leads to NODD, but not 2OG,
displacement, suggesting that the aﬃnity of CODD to tPHD2 is
higher than NODD, consistent with previous work.12,22 Addition of
hyCODD manifests displacement of 2OG and NODD (Fig. S19,
ESI†), implying competition with both. Inhibition of the tPHD2-
catalysed 2OG turnover to succinate was observed by 1HNMR in the
presence of hyCODD with CODD as a substrate and, to a greater
extent, with NODD as a substrate (Fig. S20, ESI†).
The results reveal 2OG binding hinders the binding of
hyCODD, but not CODD/NODD, to the tPHD2metal2OG
complex. Thus, competition with 2OG can promote release of
prolyl hydroxylated HIF-1a from tPHD2 (and by implication
other PHD/HIF-a isoform combinations), so enabling HIF-a
degradation.4,5 Once the trans-4-hydroxyproline is formed, the
‘gauche’ stereoelectronic eﬀect biases the conformation towards
the C4-exo form, as observed in the hyCODDpVHL complex.4,5,17
Formation of the C4-exo conformation at the tPHD active site may
thus promote a clash between the hyCODD alcohol and the 2OG
C1 carboxylate, which is involved in Fe(II) chelation (Fig. S10, ESI†).
Hydroxylated prolyl HIF (hyHIF)-a is upregulated in many
tumour cells.26 Under cellular circumstances when there is
accumulation of hyHIF-a (e.g. due to mutations to the gene
encoding for pVHL as occurs in the VHL disease),27,28 or if iron
(e.g. in anaemia) or 2OG availability is limiting (e.g. potentially due to
mutations in the genes encoding for isocitrate dehydrogenase),29,30
cellular formation of the PHDFehyHIF-a or PHDhyHIF-a
complexes may become substantial, with consequent potential
limitation of the HIF-mediated hypoxic response. The results
thus suggest a negative feedback mechanism for PHD activity,
which is linked to TCA cycle metabolism.
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